Skip to main content
Premium Trial:

Request an Annual Quote

Array Shop HTG Closes $3.4M in Series B Financing Round

NEW YORK, May 4 (GenomeWeb News) - HTG, a gene expression assay-technology company, has closed $3.4 million in a Series B round of private-equity financing, the company said today.

 

The cash brings to $4.6 million in total venture capital HTG has obtained to date.

 

HTG will use the funds to expand manufacturing, sales, and marketing activities; hire additional staff; and increase product trials to support its ArrayPlate qNPA technology.

 

Participating in the financing round were Solstice Capital, Valley Ventures, Emerging Technology Partners, Deimos Ventures, Village Ventures, members of the Tucson Desert Angels, and HTG founder Bruce Seligmann.

 

Solstice Capital, Valley Ventures, and Village Ventures participated in HTG's first round of financing in 2002.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.